<DOC>
	<DOCNO>NCT02959918</DOCNO>
	<brief_summary>This open label multicenter study evaluate safety tolerability multiple dos ( 3 monthly IV infusion ) SEL-212 ( combination pegsiticase ( SEL-037 ) SVP-rapamycin ( SEL-110 ) ) follow multiple dos ( 2 monthly IV infusion ) pegsiticase ( SEL-037 ) alone total 5 treatment cycle subject symptomatic gout hyperuricemia . Additional subject treat multiple dos ( 5 monthly IV infusion ) pegsiticase ( SEL-037 ) alone . Subjects monitor safety endpoint 5th treatment cycle plus 30 day .Pharmacokinetic sample draw pre-determined time point addition weekly serum uric acid level .</brief_summary>
	<brief_title>Multi-Dose Safety/Pharmacodynamic Study SEL-212/SEL-037 Subjects With Symptomatic Gout &amp; Elevated Blood Uric Acid</brief_title>
	<detailed_description>This open label multicenter study evaluate safety tolerability multiple dos ( 3 monthly IV infusion ) SEL-212 ( combination pegsiticase ( SEL-037 ) SVP-rapamycin ( SEL-110 ) ) follow multiple dos ( 2 monthly IV infusion ) pegsiticase ( SEL-037 ) alone total 5 treatment cycle subject symptomatic gout hyperuricemia . Additional subject treat multiple dos ( 5 monthly IV infusion ) pegsiticase ( SEL-037 ) alone . Uricase enzyme convert uric acid readily soluble allantoin excrete SEL-110 design prevent unwanted anti-drug-antibodies ( ADAs ) forming . All subject monitor safety tolerability drug throughout study weekly schedule . Pharmacokinetic pharmacodynamic parameter specific timepoints monitor continued efficacy . Pharmacodynamic parameter measure include uric acid level level ADAs . The study duration per enrol subject approximately 6 month include 1 month screen period follow 5 treatment cycle end treatment visit occur 30 day last IV infusion .</detailed_description>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>1 . Adult ( age 2175 inclusive ) men woman non child bearing potential establish symptomatic gout define least ONE 3 follow factor : 1 . ≥ 1 tophus 2 . 1 gout flare within last 6 month 3 . Chronic gouty arthropathy 2 . Screening serum uric acid &gt; 6ng/dL 3 . On gout flare prophylactic regimen 7 day prior first dose 4 . Willing provide write informed consent prior first study procedure perform . 5 . Understands willing able comply study requirement , include schedule followup visit . 1 . History anaphylaxis severe allergic reaction . 2 . History allergy pegylated product . 3 . Women child bear potential , Defined : &lt; 6 week surgical bilateral salpingooperhectony without hysterectomy Pre perimenopausal ( &lt; less 24 month natural amenorrhea ) 4 . Initiation change dose hormonereplacement therapy menopausal woman less 1 month prior Screening Visit Screening Phase would exclusionary . If stable dose hormonereplacement therapy one month patient may consider study continue meet inclusion exclusion criterion 5 . Uncontrolled diabetes baseline HbA1c ≥8 % ; 6 . Glucose6phosphate dehydrogenase deficiency ; 7 . Uncontrolled hypertension 8 . Ongoing treatment arrhythmia , include placement implantable defibrillator ; 9 . History coronary artery disease , include myocardial infarction ; 10 . Congestive heart failure , New York Heart Association Class III IV ; 11 . ECG evidence prior myocardial infarction , clinically significant arrhythmia , abnormality , opinion investigator , consistent significant underlying cardiac disease ; 12 . History hematological autoimmune disorder , immunosuppressed immunocompromised ; 13 . Prior exposure experimental market uricase ( e.g. , rasburicase ( Elitek , Fasturtec ) , pegloticase ( Krystexxa® ) , pegsiticase ( SEL037 ) 14 . History malignancy within last 5 year basal skin cancer ; 15 . Subjects , opinion investigator , present condition would compromise safety would make study completion unlikely .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>